As women approach perimenopause, many experience unexpected weight gain, despite maintaining healthy lifestyles. Jana Stewart, 54, a hormone and midlife health coach and bodybuilder, faced this issue firsthand, gaining around 15 pounds that she could not shed through her usual routines. “Suddenly, everything that used to work perfectly just stopped working,” she shared. In search of solutions, her hormone specialist recommended Wegovy, a GLP-1 receptor agonist.
Wegovy, along with similar medications like Ozempic, Zepbound, and Mounjaro, is a synthetic version of the GLP-1 hormone, which helps regulate blood sugar, appetite, and feelings of fullness. After initially using a full dose to lose weight, Stewart transitioned to micro-dosing, taking just 10 units weekly to maintain her target weight of 125 pounds. She noted that micro-dosing has shifted her focus from weight loss to managing cravings and inflammation, crucial for alleviating perimenopausal symptoms.
Weight gain during menopause is not uncommon. Dr. Roxanne Pero, an OBGYN and member of O Positiv’s Medical Advisory Board, states that 60 to 70 percent of women in midlife report weight gain during this transition, with total gain often reaching 22 to 25 pounds.
“Weight gain during menopause is incredibly common,” says Dr. Roxanne Pero.
This phenomenon is particularly pronounced among Black women, who often enter menopause with higher body weights and more abdominal fat compared to their White counterparts. Dr. Pero explains that while they might not gain as much additional weight during menopause, they tend to retain existing body fat and may see further weight gain post-menopause.
Amid these challenges, many women have turned to GLP-1 medications like Wegovy to manage stubborn pounds. Notable figures such as Serena Williams, Whoopi Goldberg, and Oprah have publicly shared their experiences with these weight loss drugs, which have gained popularity across the United States. One in eight Americans have reportedly tried GLP-1 medications, underlining their widespread appeal.
Dr. Melynda Barnes, chief medical officer at Ro, highlights the effectiveness of these medications. “GLP-1 medications like Ozempic and Wegovy are the most effective tools to help people successfully manage their weight by increasing feelings of fullness and regulating blood sugar,” she explains.
Stewart’s experience with Wegovy was largely positive, as she quickly lost weight. Though, she also encountered some changes in her body, including loose skin and initial muscle loss. She acknowledged the importance of adjusting her weight training regimen in response to the medication. Some women have reported side effects such as hair loss and changes in body appearance, contributing to hesitancy around starting these treatments. The recent availability of GLP-1 pills may simplify dosing for users.
Despite the benefits, concerns about the safety of GLP-1 medications have emerged. Since 2023, class action lawsuits have been filed against manufacturers like Novo Nordisk and Eli Lilly, claiming that these drugs can cause severe side effects such as gastroparesis, which was not included on the warning labels. Symptoms of gastroparesis include nausea, vomiting, and bloating, as it affects the stomach’s ability to process food.
As of 2026, over 3,000 lawsuits related to gastrointestinal injuries and 29 alleging vision loss are pending. While GLP-1s were first approved for type 2 diabetes in 2005, their popularity for weight loss surged after the introduction of Ozempic in 2017. This rapid rise raises questions about the long-term risks associated with their use.
It’s crucial to note that adverse effects associated with GLP-1s are not solely tied to higher doses; many allegations suggest that these side effects can worsen with prolonged use or increased dosages. Micro-dosing may mitigate some of these issues, as side effects tend to be milder during the adjustment period.
However, micro-dosing during menopause presents its own challenges. Dr. Pero warns that hormonal fluctuations can exacerbate issues such as muscle loss and hair thinning. Maintaining adequate protein intake, nutrient-dense meals, and regular weight training is essential for preserving muscle mass.
Despite these challenges, many women identify that the advantages of micro-dosing outweigh the potential downsides. Dr. Sarah De La Torre, a double board certified physician, has observed positive results among her patients using Tirzepatide at micro-doses, including decreased inflammation, weight loss, and enhanced mental clarity. She describes these benefits as “extremely beneficial” for women in menopause.
Jana Stewart noted an increase in both energy and mood after starting Wegovy, alongside a surprising reduction in her desire for alcohol. “It really curbs your desire to drink alcohol,” she stated, reflecting on the medication’s broader impact on her lifestyle.
While micro-dosing GLP-1s can be a promising approach for managing menopausal weight gain, it is crucial to have open discussions about the potential risks and benefits associated with these medications. Many women, like Stewart, may experience isolated in their struggles, unaware of the options available to them. Whether through GLP-1s, community support, or lifestyle adjustments, resources are accessible, and it is vital to utilize them.
Understanding the implications of GLP-1 use and its role in women’s health remains an evolving conversation. As more research unfolds, it is essential for women to stay informed and proactive about their health choices. Engaging with healthcare providers to discuss available options can empower women during this transitional phase of life.
